<meta charset="utf8"></head><body>使用野生型封闭 PCR 优化低频突变检测

<ol><li>Penn Medicine. Testing for measurable/minimal residual disease (MRD). , Oncolink Team. 
 <a target="_blank" href="https://www.oncolink.org/cancer-treatment/procedures-diagnostic-tests/blood-tests-tumordiagnostic-tests/testing-for-measurable-minimal-residualdisease-mrd">https://www.oncolink.org/cancer-treatment/procedures-diagnostic-tests/blood-tests-tumordiagnostic-tests/testing-for-measurable-minimal-residualdisease-mrd</a> (2019).</li>
<li>Xie, Y., Elaine, S. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((How+I+diagnose+angioimmunoblastic+T-cell+lymphoma%5BTitle%5D)+AND+%22Am+J+Clin+Pathol%22%5BJournal%5D)">How I diagnose angioimmunoblastic T-cell lymphoma.</a> Am J Clin Pathol. 156, 1-14 (2021).</li>
<li>Mariko, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Angioimmunoblastic+T-cell+lymphoma%5BTitle%5D)+AND+%22Cancer+Treat+Res%22%5BJournal%5D)">Angioimmunoblastic T-cell lymphoma.</a> Cancer Treat Res. 176, 99-126 (2019).</li>
<li>Daniel, A. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+2016+revision+to+the+World+Health+Organization+classification+of+myeloid+neoplasms+and+acute+lukemia%5BTitle%5D)+AND+%22Blood%22%5BJournal%5D)">The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute lukemia.</a> Blood. 127 (20), 2391-2405 (2016).</li>
<li>Rita, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+5th+edition+of+the+World+Health+Organization+Classification+of+Haematolymphoid+Tumours+%3A+Lymphoid+Neoplasms%5BTitle%5D)+AND+%22Leukemia%22%5BJournal%5D)">The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours : Lymphoid Neoplasms.</a> Leukemia. 36 (7), 1720-1748 (2022).</li>
<li>Hae, Y. Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+recurrent+inactivating+mutation+in+RHOA+GTPase+in+angioimmunoblastic+T+cell+lymphoma%5BTitle%5D)+AND+%22Nat+Genet%22%5BJournal%5D)">A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma.</a> Nat Genet. 46 (4), 371-375 (2014).</li>
<li>Lee, P. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((RHOA+G17V+mutation+in+angioimmunoblastic+T-cell+lymphoma%3AA+potential+biomarker+for+cytological+assessment%5BTitle%5D)+AND+%22Exp+Mol+Pathol%22%5BJournal%5D)">RHOA G17V mutation in angioimmunoblastic T-cell lymphoma:A potential biomarker for cytological assessment.</a> Exp Mol Pathol. 110, 104294(2019).</li>
<li>Mamiko, S. Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Somatic+RHOA+mutation+in+angioimmunoblastic+T+cell+lymphoma%5BTitle%5D)+AND+%22Nat+Genet%22%5BJournal%5D)">Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.</a> Nat Genet. 46 (2), 171-175 (2014).</li>
<li>Palomero, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Recurrent+mutations+in+epigenetic+regulators%2C+RHOA+and+FYN+kinase+in+peripheral+T+cell+lymphomas%5BTitle%5D)+AND+%22Nat+Genet%22%5BJournal%5D)">Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.</a> Nat Genet. 46 (2), 166-170 (2014).</li>
<li>Fujisawa, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Activation+of+RHOA-VAV1+signaling+in+angioimmunoblastic+T-cell+lymphoma%5BTitle%5D)+AND+%22Leukemia%22%5BJournal%5D)">Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.</a> Leukemia. 32 (3), 694-702 (2018).</li>
<li>Voena, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((RHO+family+GTPases+in+the+biology+of+lymphoma%5BTitle%5D)+AND+%22Cells%22%5BJournal%5D)">RHO family GTPases in the biology of lymphoma.</a> Cells. 8 (7), 646(2019).</li>
<li>Shendure, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((DNA+sequencing+an+40%3A+past%2C+present+and+future%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">DNA sequencing an 40: past, present and future.</a> Nature. 550 (7676), 345-353 (2017).</li>
<li>Athanasios, C. T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Comparison+of+Sanger+sequencing%2C+pyrosequencing%2C+and+melting+curve+analysis+for+the+detection+of+KRAS+mutations%3A+diagnostic+and+clinical+implications%5BTitle%5D)+AND+%22J+Mol+Diagn%22%5BJournal%5D)">Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications.</a> J Mol Diagn. 12 (4), 425-432 (2010).</li>
<li>Wu, L. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Multiplexed+enrichment+of+rare+DNA+variants+via+sequence-selective+and+temperature-robust+amplification%5BTitle%5D)+AND+%22Nat+Biomed+Eng%22%5BJournal%5D)">Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification.</a> Nat Biomed Eng. 1, 714-723 (2017).</li>
<li>John, S. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+thermodynamics+of+DNA+structural+motifs%5BTitle%5D)+AND+%22Annu+Rev+Biophys+Biomol+Struct%22%5BJournal%5D)">The thermodynamics of DNA structural motifs.</a> Annu Rev Biophys Biomol Struct. 33, 415-440 (2004).</li>
<li>Coren, A. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((PCR-based+methods+for+the+enrichment+of+minority+alleles+and+mutations%5BTitle%5D)+AND+%22Clin+Chem%22%5BJournal%5D)">PCR-based methods for the enrichment of minority alleles and mutations.</a> Clin Chem. 55 (4), 632-640 (2009).</li>
<li>Eliza, M. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Circulating+tumor+DNA+in+B-cell+lymphoma%3A+technical+advances%2C+clinical+applications%2C+and+perspectives+for+translational+research%5BTitle%5D)+AND+%22Leukemia%22%5BJournal%5D)">Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.</a> Leukemia. 36 (9), 2151-2164 (2022).</li>
<li>Lee, H. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hot-spot-specific+probe+%28HSSP%29+for+rapid+and+accurate+detection+of+KRAS+mutations+in+colorectal+cancer%5BTitle%5D)+AND+%22Biosensors%22%5BJournal%5D)">Hot-spot-specific probe (HSSP) for rapid and accurate detection of KRAS mutations in colorectal cancer.</a> Biosensors. 12 (8), 597(2022).</li>
<li>Matsubara, R. N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Detection+of+the+G17V+RHOA+mutation+in+angioimmunoblastic+T-cell+lymphoma+and+related+lymphomas+using+quantitative+allele-specific+PCR%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">Detection of the G17V RHOA mutation in angioimmunoblastic T-cell lymphoma and related lymphomas using quantitative allele-specific PCR.</a> PLoS One. 9 (10), e109714(2014).</li>
<li>Dieffenbach, C. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((General+concepts+for+PCR+primer+design%5BTitle%5D)+AND+%22PCR+Methods+Appl%22%5BJournal%5D)">General concepts for PCR primer design.</a> PCR Methods Appl. 3 (3), S30-S37 (1993).</li>
<li>Applied Biosystems. User Guide for Applied Biosystems. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=%223730%2F3730xl+DNA+Analyzer%22">3730/3730xl DNA Analyzer</a>. , (2014).</li>
</ol>

<table><tbody><tr><td>Automatic DNA extractor</td><td>9001301</td><td>Qiagen</td><td></td></tr><tr><td>DNA nucleic acid detector</td><td>Q32854</td><td>Thermo fisher</td><td></td></tr><tr><td>PCR amplification kit</td><td>P4600</td><td>merck</td><td></td></tr><tr><td>PCR instrument</td><td>C1000 Touch</td><td>Biorad</td><td></td></tr><tr><td>proteinase K solution</td><td>D3001-2-A</td><td>zymo research</td><td></td></tr><tr><td>proteinase K storage buffer</td><td>D3001-2-C</td><td>zymo research</td><td></td></tr><tr><td>Sequencing amplification enzyme kit</td><td>P7670-FIN</td><td>Qiagen</td><td></td></tr></tbody></table>

wild-type blocking pcr combined with sanger sequencing for detection of low-frequency somatic mutation

<meta charset="utf8"></head><body>作者聚焦:推进癌症组织中低频突变的检测

野生型封闭 PCR 联合 Sanger 测序检测低频体细胞突变

When monitoring minimal residual disease (MRD) after tumor treatment, there are higher requirements of the lower limit of detection than when detecting ...

wild-type-blocking-pcr-combined-with-sanger-sequencing-for-detection

Research

JoVE Journal

Genetics

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

1.1K 次观看.  Kindstar Global Technology Inc.. 我们对了解癌组织中的低频体细胞突变感兴趣。本文介绍了基于我们的 Sanger 测序的低频突变检测方法在血管免疫母细胞淋巴瘤检测中的应用，为该方法应用于其他疾病检测提供了依据。目前有定量 PCR、数字 PCR 和 NGS 等低频突变检测方法。但尚无基于 Sanger 测序检测 IGHV7-3 低频突变的报道，其中检出限仅为 5%-20%一般由于技术限制，基于 Sanger 测...

视频: 作者聚焦:推进癌症组织中低频突变的检测

Methyl-binding DNA capture Sequencing for Patient Tissues

Methylation is one of the essential epigenetic modifications to the DNA, which is responsible for the precise regulation of genes required for stable development and differentiation of different tissue types. Dysregulation of this process is often the hallmark of various diseases like cancer. Here, we outline one of the recent sequencing techniques, Methyl-Binding DNA Capture sequencing (MBDCap-seq), used to quantify methylation in various normal and disease tissues for large patient cohorts. We describe a detailed protocol of this affinity enrichment approach along with a bioinformatics pipeline to achieve optimal quantification. This technique has been used to sequence hundreds of patients across various cancer types as a part of the 1,000 methylome project (Cancer Methylome System).

Here we present a protocol to investigate genome wide DNA methylation in large scale clinical patient screening studies using the Methyl-Binding DNA Capture sequencing (MBDCap-seq or MBD-seq) technology and the subsequent bioinformatics analysis pipeline.

为患者组织甲基结合DNA序列捕获

Methylation is one of the essential epigenetic modifications to the DNA, which is responsible for the precise regulation of genes required for stable ...

科研

遗传学

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations

Accurate detection and identification of low frequency mutations can be problematic when assessing residual disease after therapy, screening for emerging resistance mutations during therapy, or when patients have few circulating tumor cells. Wild-type blocking PCR followed by sequencing analysis offers high sensitivity, flexibility, and simplicity as a methodology for detecting these low frequency mutations. By adding a custom designed locked nucleic acid oligonucleotide to a new or previously established conventional PCR based sequencing assay, sensitivities of approximately 1 mutant allele in a background of 1,000 WT alleles can be achieved (1:1,000). Sequencing artifacts associated with deamination events commonly found in formalin fixed paraffin embedded tissues can be partially remedied by the use of uracil DNA glycosylase during extraction steps. The optimized protocol here is specific for detecting MYD88 mutation, but can serve as a template to design any WTB-PCR assay. Advantages of the WTB-PCR assay over other commonly utilized assays for the detection of low frequency mutations including allele specific PCR and real-time quantitative PCR include fewer occurrences of false positives, greater flexibility and ease of implementation, and the ability to detect both known and unknown mutations.

Wild-type blocking PCR followed by direct sequencing offers a highly sensitive method of detection for low frequency somatic mutations in a variety of sample types.

野生类型阻止PCR结合直接测序作为低频体细胞突变的检测的高灵敏度的方法

Accurate detection and identification of low frequency mutations can be problematic when assessing residual disease after therapy, screening for emerging ...

Detection of Copy Number Alterations Using Single Cell Sequencing

Detection of genomic changes at single cell resolution is important for characterizing genetic heterogeneity and evolution in normal tissues, cancers, and microbial populations. Traditional methods for assessing genetic heterogeneity have been limited by low resolution, low sensitivity, and/or low specificity. Single cell sequencing has emerged as a powerful tool for detecting genetic heterogeneity with high resolution, high sensitivity and, when appropriately analyzed, high specificity. Here we provide a protocol for the isolation, whole genome amplification, sequencing, and analysis of single cells. Our approach allows for the reliable identification of megabase-scale copy number variants in single cells. However, aspects of this protocol can also be applied to investigate other types of genetic alterations in single cells.

Single cell sequencing is an increasingly popular and accessible tool for addressing genomic changes at high resolution. We provide a protocol that uses single cell sequencing to identify copy number alterations in single cells.

单细胞测序拷贝数改变的检测

Detection of genomic changes at single cell resolution is important for characterizing genetic heterogeneity and evolution in normal tissues, cancers, and ...

Detection of microRNA Expression in Peritoneal Membrane of Rats Using Quantitative Real-time PCR

MicroRNAs (miRNAs) are small noncoding RNAs that regulate messenger RNA expression post-transcriptionally. The miRNA expression profile has been investigated in various organs and tissues in rat. However, standard methods for the purification of miRNAs and detection of their expression in rat peritoneal membrane have not been well established. We have developed an effective and reliable method to purify and quantify miRNAs using quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR) in rat peritoneal membrane. This protocol consists of four steps: 1) purification of peritoneal membrane sample; 2) purification of total RNA including miRNA from peritoneal membrane sample; 3) reverse transcription of miRNA to produce cDNA; and 4) qRT-PCR to detect miRNA expression. Using this protocol, we successfully determined that the expression of six miRNAs (miRNA-142-3p, miRNA-21-5p, miRNA-221-3p, miRNA-223-3p, miRNA-327, and miRNA-34a-5p) increased significantly in the peritoneal membrane of a rat peritoneal fibrosis model compared with those in control groups. This protocol can be used to study the profile of miRNA expression in the peritoneal membrane of rats in many pathological conditions.

Here we present a protocol for the detection of microRNA expression in rat peritoneal membrane using quantitative real-time reverse-transcription polymerase chain reaction. This method is suitable for studying the microRNA expression profile in rat peritoneal membrane in several pathological conditions.

使用定量实时PCR检测大鼠腹膜中的微小RNA表达

MicroRNAs (miRNAs) are small noncoding RNAs that regulate messenger RNA expression post-transcriptionally. The miRNA expression profile has been ...

Rare Event Detection Using Error-corrected DNA and RNA Sequencing

Conventional next-generation sequencing techniques (NGS) have allowed for immense genomic characterization for over a decade. Specifically, NGS has been used to analyze the spectrum of clonal mutations in malignancy. Though far more efficient than traditional Sanger methods, NGS struggles with identifying rare clonal and subclonal mutations due to its high error rate of ~0.5&#8211;2.0%. Thus, standard NGS has a limit of detection for mutations that are &#62;0.02 variant allele fraction (VAF). While the clinical significance for mutations this rare in patients without known disease remains unclear, patients treated for leukemia have significantly improved outcomes when residual disease is &#60;0.0001 by flow cytometry. In order to mitigate this artefactual background of NGS, numerous methods have been developed. Here we describe a method for Error-corrected DNA and RNA Sequencing (ECS), which involves tagging individual molecules with both a 16 bp random index for error-correction and an 8 bp patient-specific index for multiplexing. Our method can detect and track clonal mutations at variant allele fractions (VAFs) two orders of magnitude lower than the detection limit of NGS and as rare as 0.0001 VAF.

Next-generation sequencing (NGS) is a powerful tool for genomic characterization that is limited by the high error rate of the platform (~0.5&#8211;2.0%). We describe our methods of error-corrected sequencing that allow us to obviate the NGS error rate and detect mutations at variant allele fractions as rare as 0.0001.

基于纠错 DNA 和 RNA 测序的稀有事件检测方法

Conventional next-generation sequencing techniques (NGS) have allowed for immense genomic characterization for over a decade. Specifically, NGS has been ...

Amplification of Near Full-length HIV-1 Proviruses for Next-Generation Sequencing

The Full-Length Individual Proviral Sequencing (FLIPS) assay is an efficient and high-throughput method designed to amplify and sequence single, near full-length (intact and defective), HIV-1 proviruses. FLIPS allows determination of the genetic composition of integrated HIV-1 within a cell population. Through identifying defects within HIV-1 proviral sequences that arise during reverse transcription, such as large internal deletions, deleterious stop codons/hypermutation, frameshift mutations, and mutations/deletions in cis acting elements required for virion maturation, FLIPS can identify integrated proviruses incapable of replication. The FLIPS assay can be utilized to identify HIV-1 proviruses that lack these defects and are&#160;therefore potentially replication-competent. The FLIPS protocol involves: lysis of HIV-1 infected cells, nested PCR of near full-length HIV-1 proviruses (using primers targeted to the HIV-1 5&#39; and 3&#39; LTR), DNA purification and quantification, library preparation for Next-generation Sequencing (NGS), NGS, de novo assembly of proviral contigs, and a simple process of elimination for identifying replication-competent proviruses. FLIPS provides advantages over traditional methods designed to sequence integrated HIV-1 proviruses, such as single-proviral sequencing. FLIPS amplifies and sequences near full-length proviruses enabling replication competency to be determined, and also uses fewer amplification primers, preventing the consequences of primer mismatches. FLIPS is a useful tool for understanding the genetic landscape of integrated HIV-1 proviruses, especially within the latent reservoir, however, its utilization can extend to any application in which the genetic composition of integrated HIV-1 is required.

Full-length individual proviral sequencing (FLIPS) provides an efficient and high-throughput method for the amplification and sequencing of single, near full-length (intact and defective) HIV-1 proviruses and allows for determination of their potential replication-competency. FLIPS overcomes limitations of previous assays designed to sequence the latent HIV-1 reservoir.

用于下一代测序的近全长 HIV-1 Proviruses 的扩增

The Full-Length Individual Proviral Sequencing (FLIPS) assay is an efficient and high-throughput method designed to amplify and sequence single, near ...

Separating Bacteria by Capsule Amount Using a Discontinuous Density Gradient

Capsule is a key virulence factor in many bacterial species, mediating immune evasion and resistance to various physical stresses. While many methods are available to quantify and compare capsule production between different strains or mutants, there is no widely used method for sorting bacteria based on how much capsule they produce. We have developed a method to separate bacteria by capsule amount, using a discontinuous density gradient. This method is used to compare capsule amounts semi-quantitatively between cultures, to isolate mutants with altered capsule production, and to purify capsulated bacteria from complex samples. This method can also be coupled with transposon-insertion sequencing to identify genes involved in capsule regulation. Here, the method is demonstrated in detail, including how to optimize the gradient conditions for a new bacterial species or strain, and how to construct and run the density gradient.

We demonstrate the use of discontinuous density gradients to separate bacterial populations based on capsule production. This method is used to compare capsule amount between cultures, isolate mutants with a specific capsule phenotype, or to identify capsule regulators. Described here is the optimization and running of the assay.

用不连续密度梯度用胶囊分离细菌

Capsule is a key virulence factor in many bacterial species, mediating immune evasion and resistance to various physical stresses. While many methods are ...

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Assessing intra-tumoral heterogeneity (ITH) is of paramount importance to anticipate failure of targeted therapies and design accordingly effective anti-tumor strategies. Although concerns are frequently raised due to differences in sample processing and depth of coverage, next-generation sequencing of solid tumors have unraveled a highly variable degree of ITH across tumor types. Capturing the genetic relatedness between primary and metastatic lesions through the identification of clonal and subclonal populations is critical to the design of therapies for advance-stage diseases. Here, we report a method for comparative lesions analysis that allows for the identification of clonal and subclonal populations among different specimens from the same patient. The experimental approach described here integrates three well-established approaches: histological analysis, high-coverage multi-lesion sequencing, and immunophenotypic analyses. In order to minimize the effects on the detection of subclonal events by inappropriate sample processing, we subjected tissues to careful pathological examination and neoplastic cell enrichment. Quality controlled DNA from neoplastic lesions and normal tissues was then subjected to high coverage sequencing, targeting the coding regions of 409 relevant cancer genes. While only looking at a limited genomic space, our approach enables evaluating the extent of heterogeneity among somatic alterations (single-nucleotide mutations and copy-number variations) in distinct lesions from a given patient. Through comparative analysis of sequencing data, we were able to distinguish clonal vs. subclonal alterations. The majority of ITH is often ascribed to passenger mutations; therefore, we also used immunohistochemistry to predict functional consequences of mutations. While this protocol has been applied to a specific tumor type, we anticipate that the methodology described here is broadly applicable to other solid tumor types.

This article describes a method to identify clonal and subclonal alterations among different specimens from a given patient. Although the experiments described here focus on a specific tumor type, the approach is broadly applicable to other solid tumors.

通过有针对性的测序方法进行比较病变分析

Assessing intra-tumoral heterogeneity (ITH) is of paramount importance to anticipate failure of targeted therapies and design accordingly effective ...

行为学

Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing

Efforts to detect and investigate key oncogenic mutations have proven valuable to facilitate the appropriate treatment for cancer patients. The establishment of high-throughput, massively parallel "next-generation" sequencing has aided the discovery of many such mutations. To enhance the clinical and translational utility of this technology, platforms must be high-throughput, cost-effective, and compatible with formalin-fixed paraffin embedded (FFPE) tissue samples that may yield small amounts of degraded or damaged DNA. Here, we describe the preparation of barcoded and multiplexed DNA libraries followed by hybridization-based capture of targeted exons for the detection of cancer-associated mutations in fresh frozen and FFPE tumors by massively parallel sequencing. This method enables the identification of sequence mutations, copy number alterations, and select structural rearrangements involving all targeted genes. Targeted exon sequencing offers the benefits of high throughput, low cost, and deep sequence coverage, thus conferring high sensitivity for detecting low frequency mutations.

We describe the preparation of barcoded DNA libraries and subsequent hybridization-based exon capture for detection of key cancer-associated mutations in clinical tumor specimens by massively parallel "next generation" sequencing. Targeted exon sequencing offers the benefits of high throughput, low cost, and deep sequence coverage, thus yielding high sensitivity for detecting low frequency mutations.

由外显子捕获和大规模平行测序检测体细胞遗传学改变在肿瘤标本

Efforts  to detect and investigate key oncogenic mutations have proven valuable to  facilitate the appropriate treatment for cancer patients. The ...

生物学

Wild-Type Blocking PCR to Detect Low-Frequency Somatic Mutations

The forward and reverse primers were designed with a 5&#39;-M13 sequence to allow for annealing of complementary sequencing primers. Design the blocking oligonucleotide to be approximately 10 to 15 bases in length and complementary to the wild-type template where mutant enrichment is desired.
A shorter oligo will improve mismatch discrimination. To achieve high target specificity, it&#39;s important not to use too much of the blocking nucleotides, as this will result in a very &#34;sticky&#34; oligonucleotide.
To design the blocking oligonucleotide, begin by navigating to the Oligo Tools website. Select the &#34;Oligo TM Prediction&#34; tool. A new window will open up. Paste the sequence of the wild-type template to be blocked into the &#34;Oligo Sequence&#34; box. Add a plus sign in front of the blocker bases to mark them. Click on the &#34;Calculate&#34; button to determine the approximate TM of the DNA blocker hybrid. The calculated melting temperatures will appear in the boxes below.
Design the blocking oligo to have a melting temperature 10 to 15 degrees Celsius above the extension temperature during thermocycling. Here, the extension temperature is 72 degrees Celsius. To adjust the melting temperature, add, remove, or substitute blocking bases. Avoid long stretches of three to four blocking C or G bases.
Next, to avoid secondary structure formation or self-dimerization, go back to the Oligo Tools website home screen and select the &#34;Oligo Optimizer&#34; tool. A new window will open. Paste the sequence of the wild-type template to be blocked into the box. Add a plus sign to indicate blocking bases. Select the two boxes for &#34;Secondary Structure&#34; and &#34;Self Only&#34; and press the &#34;Analyze&#34; button to see the scores for hybridization and secondary structure.
These scores represent very rough estimates of the melting temperatures of the self-dimers and secondary structures, respectively. Lower scores are optimal and can be achieved by limiting blocker-blocker pairing. Remove or reposition blocking nucleotides in order to achieve lower scores. The optimized blocking oligonucleotide for MyD88, shown here, strikes a balance between the DNA blocker hybrid melting temperature and low enough hybridization and secondary structure scores.
It was designed to cover amino acids Q262 to I266 and features a 3&#39;-inverted dT to inhibit both extension by DNA polymerase and degradation by 3&#39;-exonuclease. Once the primers have been designed, set up the wild-type blocking PCR and perform thermocycling, as described in the accompanying document.